Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
McKinsey
Mallinckrodt
Dow

Last Updated: August 19, 2022

Investigational Drug Information for DAS181


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for DAS181?

DAS181 is an investigational drug.

There have been 14 clinical trials for DAS181. The most recent clinical trial was a Phase 2 trial, which was initiated on May 23rd 2019.

The most common disease conditions in clinical trials are Influenza, Human, COVID-19, and Paramyxoviridae Infections. The leading clinical trial sponsors are Ansun Biopharma, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and National Institutes of Health (NIH).

There are three US patents protecting this investigational drug and thirty-nine international patents.

Recent Clinical Trials for DAS181
TitleSponsorPhase
DAS181 for STOP COVID-19Ansun Biopharma, Inc.Phase 2/Phase 3
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)Ansun Biopharma, Inc.Phase 2
DAS181 for Severe COVID-19: Compassionate UseAnsun Biopharma, Inc.N/A

See all DAS181 clinical trials

Clinical Trial Summary for DAS181

Top disease conditions for DAS181
Top clinical trial sponsors for DAS181

See all DAS181 clinical trials

US Patents for DAS181

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DAS181 See Plans and Pricing Treatment of infection by human enterovirus D68 Ansun Biopharma, Inc. (San Diego, CA) See Plans and Pricing
DAS181 See Plans and Pricing 2'-substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (Foster City, CA) See Plans and Pricing
DAS181 See Plans and Pricing Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture Ansun Biopharma, Inc. (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for DAS181

Drugname Country Document Number Estimated Expiration Related US Patent
DAS181 World Intellectual Property Organization (WIPO) WO2016044656 2034-09-17 See Plans and Pricing
DAS181 Australia AU2013232378 2032-03-13 See Plans and Pricing
DAS181 Australia AU2017279590 2032-03-13 See Plans and Pricing
DAS181 Brazil BR122016003311 2032-03-13 See Plans and Pricing
DAS181 Canada CA2866381 2032-03-13 See Plans and Pricing
DAS181 China CN104185638 2032-03-13 See Plans and Pricing
DAS181 China CN106749272 2032-03-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
McKinsey
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.